世界のC型肝炎ウイルス(HCV)抗ウイルス薬市場：製品・パイプライン分析

世界のHCV向け治療薬市場では現在、インターフェロンが不要な完全経口薬(All-oral Regimens)の開発が進められており、それが今後の市場環境を劇的に変化させる可能背があります。

当レポートでは、全世界のC型肝炎ウイルス(HCV)向け抗ウイルス薬の市場について分析し、上市済み／開発中の製品に関するパイプライン情報や、治験の進行状況と成果、主要市場の動向、過去・将来の製品上市動向、HCVの疫学的情報などの情報をお届けします。

第1章　エグゼクティブ・サマリー

• 市場の最新動向
• 主な分析結果
• C型肝炎ウイルス(HCV)の標準治療の進化
• 注目すべき企業

第2章　分析手法・対象

第3章　イントロダクション

• C型肝炎ウイルス(HCV)の概要
• 世界各地の慢性HCV有病者の分布
• HCVの遺伝子型別の分布状況および関連有病者数
• HCV抗ウイルス薬市場の構造

第4章　競争分析

• 競争環境：上市済み製品および開発中の製品
• 競争環境：治験最終段階の完全経口薬(All-oral Regimens)の治験データ
• 競争環境：経口薬の上市予定表
• 競争環境：治験第III相にある主な完全経口薬
• 競争環境：治験最終段階の製品群：企業別・クラス別
• 上市済み製品の概要：標準治療
• 上市済み製品の概要：標準治療への付加治療
• 上市済み製品の概要：世界各地での導入状況
• パイプライン製品の概要：治験段階にある完全経口薬
• パイプライン製品の概要：治験最終段階の製品の開発環境
• パイプライン製品の概要：治験初期段階の製品の開発環境

第5章　結論と提言

• 結論と提言
• 法的免責事項

第6章　付録

• 意思決定支援データベース

第7章　FROST & SULLIVANについて

All-oral Regimens Revolutionize the Market

This research service focuses on antiviral therapeutics for the treatment of the hepatitis C virus (HCV). A global product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HCV. Segmentation by drug class is provided, along with supporting information such as clinical trial timelines and results, key market developments, historical and projected launch timelines, and epidemiology. The information contained in this research was derived from published sources, including disease organizations; public health organizations; company publications including annual reports, SEC filings, and press releases; government public sources; and articles in scientific journals.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

• 1. Key Market Developments Since Q1 2013
• 2. Key Findings
• 3. Evolution of Standard of Care for HCV
• 4. Key Companies to Watch

2. METHODOLOGY AND SCOPE

Methodology and Scope

• 1. Methodology and Scope

3. INTRODUCTION

Introduction

• 1. HCV Overview
• 2. Global Prevalence of Chronic HCV Infection by Region
• 3. Global HCV Genotype Distribution and Relative Prevalence
• 4. HCV Antiviral Market-Segmentation
• 5. HCV Antiviral Market-Segmentation (continued)

4. COMPETITIVE ANALYSIS

Competitive Analysis

• 1. Competitive Landscape-Marketed Products and Products in Development
• 2. Competitive Landscape-All-oral Regimens Late Stage Clinical Data
• 3. Competitive Landscape-Projected Launch Timeline for Oral Regimens
• 4. Competitive Landscape-Major Phase 3 Trials for All-oral Regimens
• 5. Competitive Landscape-Major Phase 3 Trials for All-oral Regimens (continued)
• 6. Competitive Landscape-Late Stage Assets by Company and Class
• 7. Marketed Products Synopsis-Standard of Care
• 8. Marketed Products Synopsis-Add-on to Standard of Care
• 9. Marketed Products Synopsis-Global Introduction by Region
• 10. Marketed Products Synopsis-Global Introduction by Region (continued)
• 11. Pipeline Synopsis-All-oral Regimens in Clinical Development
• 12. Pipeline Synopsis-All-oral Regimens in Clinical Development (continued)
• 13. Pipeline Synopsis-All-oral Regimens in Clinical Development (continued)
• 14. Pipeline Synopsis-Late Stage Clinical Development Landscape
• 15. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
• 16. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
• 17. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
• 18. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
• 19. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
• 20. Pipeline Synopsis-Early Clinical Development Landscape
• 21. Pipeline Synopsis-Early Clinical Development Landscape (continued)
• 22. Pipeline Synopsis-Early Clinical Development Landscape (continued)

5. CONCLUSIONS AND RECOMMENDATIONS

Conclusions and Recommendations

• 1. Conclusions and Recommendations
• 2. Conclusions and Recommendations (continued)
• 3. Legal Disclaimer

6. APPENDIX

Appendix

• 1. Decision Support Database
• 2. Decision Support Database (continued)
• 3. Decision Support Database (continued)
• 4. Decision Support Database (continued)

7. THE FROST & SULLIVAN STORY

The Frost & Sullivan Story

• 1. The Frost & Sullivan Story
• 2. Value Proposition
• 3. Global Perspective
• 4. Industry Convergence
• 5. 360° Research Perspective
• 6. Implementation Excellence
• 7. Our Blue Ocean Strategy